DNTOX
Key Facts
| Invested since | 2023 |
| Based in | North Rhine-Westphalia |
About the company
DNTOX GmbH was founded in March 2022 as a spin-off from the IUF – Leibniz Institute for Environmental Medicine Research and is based on the longstanding research work of Professor Dr. Ellen Fritsche, medical scientist and toxicologist at the IUF. The team of the founders Prof. Fritsche, the economist Silke Beaucamp, the biotechnologists Dr. Katharina Koch and Dr. Kristina Bartmann as well as the bioinformaticians Dr. Arif Dönmez and Prof. Axel Mosig could already be completed by three full-time employees.
Do you want to
know more about this company?
DNTOX in the news
More startups from Life Sciences
MDTB stands for drugs, which are based on the immunomodulating drug substance Desacell®. Desacell® is an advanced drug platform based on MSC (Mesenchymal Stromal Cells) and addresses many inflammatory-associated diseases …
To the complete profileof MDTB Cell Manufacturing
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics
PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the …
To the complete profileof PraxisEins
IOP GmbH will initiate a paradigm chance in glaucoma therapy by its products for telemetric, 24 hour monitoring of intraocular pressure, allowing personalized patient management.
To the complete profileof Implandata Ophthalmic Products
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
FundaMental Pharma GmbH (FMP) is developing new types of drugs that act as ‘molecular spacers’ and disrupt a death signaling complex in the brain. Using this pharmacological strategy, FMP scientists …
To the complete profileof FundaMental Pharma
Nia Health is a spin-off of the Charité Universitätsmedizin Berlin. The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. …
To the complete profileof Nia Health
WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is …
To the complete profileof WMT
Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility …
To the complete profileof Tacalyx
O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life …
To the complete profileof O11 biomedical
Exit
m2p-labs supplies microbioreactor systems focusing on micro fermentations and automated solutions for screening and bioprocess development. The product portfolio comprises high-throughput BioLector® micro fermentation systems, microtiter FlowerPlate® plates, and automated …
To the complete profileof m2p-labs
CustomSurg, founded in 2021, is a Spin-Off from ETH Zurich and Harvard University. The company is developing software-as-a-medical-device (SaMD) solutions for the optimal selection and placement of orthopaedic implants in …
To the complete profileof CustomSurg